Daxor Corporation (DXR)vsWest Pharmaceutical Services Inc (WST)
DXR
Daxor Corporation
$8.78
-2.12%
HEALTHCARE · Cap: $56.92M
WST
West Pharmaceutical Services Inc
$403.64
+1.34%
HEALTHCARE · Cap: $28.03B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 10608318% more annual revenue ($3.33B vs $31,360). DXR leads profitability with a 19861.0% profit margin vs 17.0%. DXR trades at a lower P/E of 8.9x. WST earns a higher WallStSmart Score of 56/100 (C).
DXR
Hold49
out of 100
Grade: D+
WST
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXR.
Margin of Safety
-43.9%
Fair Value
$171.03
Current Price
$403.64
$232.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 19861 of every $100 in revenue as profit
Earnings expanding 329.3% YoY
Every $100 of equity generates 23 in profit
Revenue surging 25.5% year-over-year
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Operating margin of -4530.0%
Trading at 9.5x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 19861.0% and operating margin at -4530.0%. Revenue growth of 25.5% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : DXR
The primary concerns for DXR are Market Cap, Piotroski F-Score, Free Cash Flow.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 51.0x leaves little room for execution misses.
Key Dynamics to Monitor
DXR profiles as a growth stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.13 — expect wider price swings.
DXR is growing revenue faster at 25.5% — sustainability is the question.
WST generates stronger free cash flow (81M), providing more financial flexibility.
Bottom Line
WST scores higher overall (56/100 vs 49/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?